Metagenomi, Inc. (MGX)
(Real Time Quote from BATS)
$6.56 USD
0.00 (0.00%)
Updated Jun 5, 2024 03:01 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MGX 6.56 0.00(0.00%)
Will MGX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for MGX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for MGX
Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference
Metagenomi reports Q1 results
Analysts Have Conflicting Sentiments on These NA Companies: Metagenomi, Inc. (MGX), Smith Douglas Homes Corp. Class A (SDHC) and PACS Group Inc (PACS)
Metagenomi’s Cutting-edge Gene-Editing Prospects and Strong Financials Merit a Buy Rating
Buy Rating Affirmed for Metagenomi, Inc. on Strong Hemophilia A Program Prospects and Gene Editing Platform Potential